BackgroundAccumulating evidence shows that a propensity towards a pro-inflammatory
status in the brain plays an important role in schizophrenia. Anti-inflammatory drugs might …

Clinical observation shows that men and women are different in prevalence, symptoms, and
responses to treatment of several psychiatric disorders, including schizophrenia. While the …

Background: The inflammatory hypothesis of schizophrenia is not new, but recently it has
regained interest because more data suggest a role of the immune system in the …

Objective Antipsychotic effects of immunomodulating drugs have been suggested; however,
a thorough, comprehensive meta-analysis on the effect and safety of anti-inflammatory add …

Gender differences in schizophrenia have been extensively researched and it is being
increasingly accepted that gonadal steroids are strongly attributed to this phenomenon. Of …

Rationale Adolescence is a developmental period of complex neurobiological change and
heightened vulnerability to psychiatric illness. As a result, understanding factors such as sex …

Objective: Recent evidence suggests that adjuvant anti-inflammatory agents could improve
the symptoms of patients with schizophrenia. However, the effects of the adjuvant anti …

There is increasing clinical and molecular evidence for the role of hormones and specifically
estrogen and its receptor in schizophrenia. A selective estrogen receptor modulator …

The peak in incidence for schizophrenia is during late adolescence for both sexes, but within
this time frame the peak is both earlier and steeper for males. Additionally, women have a …

Gender differences in schizophrenia have been noted since conceptualisation of the illness.
Female onset is typically later, with a second peak post-menopause. Whilst incidence is …